[In vitro maturation and fertilization of oocytes from unstimulated cycles in women with infertility due to polycystic ovary syndrome]

Zhonghua Fu Chan Ke Za Zhi. 2005 Jun;40(6):388-91.
[Article in Chinese]

Abstract

Objective: To investigate the effect of in vitro maturation (IVM) and fertilization of oocytes from unstimulated cycles in women with infertility due to polycystic ovary syndrome (PCOS).

Methods: Seventy women with PCOS, who came to our clinic during March to were involved in this trial. June 2003. Every cycle was given human chorionic gonadotropin 10,000 IU 36 h before oocyte retrieval. Immature oocytes were matured in vitro and fertilized, and the resulting embryos were replaced back to the uterus.

Results: A total of 94 IVM cycles were performed and 1283 oocytes were obtained. The overall maturation, fertilization and cleavage rates were 65.3%, 66.0% and 48.0% respectively. Maturation, fertilization, cleavage and high quality embryo rates had no difference between metaphase I stage oocytes (69.7%, 71.7%, 52.2% and 26.1% respectively) and germinal vesical (GV) stage oocytes (67.7%, 66.4%, 47.6% and 24.1% respectively), but the rates in those oocytes which could not be classified (44.8%, 53.8%, 46.2% and 16.9% respectively) were much lower than the former two groups. After embryo transfer, 18 pregnancies were reported (24%).

Conclusion: IVM/IVF-ET in unstimulated cycles is a feasible treatment for women with PCOS.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cells, Cultured
  • Chorionic Gonadotropin / administration & dosage
  • Embryo Transfer
  • Female
  • Fertilization in Vitro
  • Humans
  • Infertility, Female / drug therapy
  • Infertility, Female / etiology
  • Infertility, Female / physiopathology*
  • Infertility, Female / therapy*
  • Oocyte Retrieval
  • Oocytes / drug effects
  • Oocytes / growth & development*
  • Polycystic Ovary Syndrome / complications*
  • Reproductive Control Agents / administration & dosage
  • Treatment Outcome

Substances

  • Chorionic Gonadotropin
  • Reproductive Control Agents